All in all, our studies provide an attractive insight in applying (−)-Guaiol into NSCLC treatments and further suggest that knockdown of oncogenic RAD51 will greatly enhance the chemosensitivity of patients with NSCLC. The gene discussed is RAD51; the disease is non-small cell lung carcinoma.